Skip to content

Characterizing Response to Antipsychotics in Schizophrenia

Schizophrenia | Schizoaffective Disorder

The goal of this research project is to develop MRI-based biomarkers to identify patients with schizophrenia who are most likely to benefit from first-line antipsychotic or clozapine treatment. The MRI sequences (NM-MRI, MRS and rsfMRI) will be created by translating the best scientific evidence into a potential clinical product that has the highest chance of being clinically relevant predictor of treatment response. This study has the potential to significantly improve patient outcomes and reduce unnecessary interventions and costs at the Royal's Integrated Schizophrenia Recovery Program.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 to 55

Participation Criteria

Inclusion Criteria:

* Are voluntary and competent to consent to the study
* Are between the ages of 18-55
* Are English literate
* Have a diagnosis of schizophrenia or schizoaffective disorder
* Are currently taking primarily olanzapine or clozapine

Exclusion Criteria:

* Medication for the treatment of schizophrenia or schizoaffective disorder has changed in the past month
* Have a significant neurologic, neurodevelopmental, cardiovascular, renal, hepatic, hematological, gastrointestinal, pulmonary, or metabolic-endocrine disorder
* Are pregnant or breastfeeding
* Acquire positive urine test result for all drugs of abuse including cannabis
* Have met DSM-5 criteria for substance use disorder other than tobacco in the last 6 months
* Have a history of significant head trauma with loss of consciousness for more than 5 minutes
* Have any contraindication to MRI
* Have any other condition that in the opinion of the investigator(s) could create a hazard to the subject's safety, endanger the study procedures, or interfere with the interpretation of study results

Study Location

The Royal's Institute of Mental Health Research
The Royal's Institute of Mental Health Research
Ottawa, Ontario
Canada

Contact Study Team

Primary Contact

Alexis Dorland

[email protected]
613-722-6521
Study Sponsored By
The Royal Ottawa Mental Health Centre
Participants Required
More Information
Study ID: NCT06159322